

# Disclosures – Scott Friedman MD

---

**Consulting:** 89 Bio, Agomab, Axcella Health, Blade Therapeutics, Can-Fite Biopharma, Cargene, Escient Pharmaceuticals, Fate Therapeutics, Forbion, Galmed, Gordian Biotechnology, Glycotest, Glympse Bio, Hepgene, In vitro, Korros Bio, Merck Pharma, Laekna, Overtone, Morphic Therapeutics, North Sea Therapeutics, Novartis, Ochre Bio, Pfizer Pharmaceuticals, Prosciento, Resolution Therapeutics, Satellite Bio, Scholar Rock, Surrozen, Yaqrit

**Stock options:** Blade Therapeutics, Escient, Galectin Galmed, Genfit, Glympse, Hepgene, Laekna, Lifemax, Metacrine, Morphic Therapeutics, Nimbus, North Sea, Therapeutics, Satellite Bio, Scholar Rock, Surrozen. **Stock ownership:** Madrigal, HueDx (formerly Group K).

**Research Activities with Commercial Entities:** Morphic Therapeutics Novo Nordisk Abalone Bio (SBIR Grant), Galmed